601 North Parkcenter Drive
About BioCorRxBioCorRx, Inc. (OTC: BICX) is a healthcare solutions company on the leading edge of addiction treatment. The company has developed a treatment program that is used by various independently owned treatment centers throughout the United States to treat alcoholism and opioid addiction.
The program consists of two components:
BioCorRx, Inc. has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol or opioids for several months and as long as a year in some patients, depending on individual metabolism rates.
BioCorRx, Inc. also developed a counseling program that is tailored specifically to help those afflicted with addiction addicts prepare for life without abuse of their desired substance. Once a patient has received the implant, they are encouraged to enter the counseling program to maximize results.
BioCorRx, Inc.’s revolutionary addiction treatment program has a very high success rate as reported by patients in routine telephone and face to face interviews conducted by clinics using the program. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private counseling program without co-workers or family members knowing.
CEO: Brady Granier
39 articles with BioCorRx
BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported on recent corporate developments. Brady Granier, CEO, and Director of BioCorRx, Inc., stated, “In light of uncertainties across many industries due to COVID-19, we wanted to reiterate that our pivotal GLP preclinical studies of BICX102, a sustai
BioCorRx Offers Free Access to the UnCraveRx™ Mobile Platform for Weight Loss Management During COVID-19 Pandemic
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering free access to the UnCraveRx™ App for a limited time. Anyone interested can download the UnCraveRx™ App online at www.myuncraverx.com or through the Android or iOS app store. The app includes cardio, strength training, endurance fitness classes that cover
BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering substance use disorder (SUD) medical professionals free access to the BioCorRx® Recovery mobile platform for a limited time to enable them to “see” their patients virtually during the coronavirus pandemic.
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use and related disorders to help save lives and improve health, today announced the promotions of Lourdes Felix to President and Tom Welch to Executive Vice President, effective immediately.
BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
ANAHEIM, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, has been awarded an additional $2.8 million. This is the second tranche from the total grant of approximately $5.7 million announced last year. The grant was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925
BioCorRx Inc., a developer and provider of advanced solutions in the treatment of substance use disorders, provided a year-end business update for 2019 and reported on recent corporate developments.
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals Provides Update on Potential Overdose Reversal Drug Candidate VDM-001
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today provided an update on VDM-001, a new opioid antagonist being developed to reverse opioid overdose
BioCorRx Inc. (BICX), based in Anaheim, CA, Leader in addiction treatment solutions and drug development implementation, today announced that Brady Granier, CEO/President and Lourdes Felix, CFO/COO, will present live at VirtualInvestorConferences.com on February 20th.
BioCorRx Inc. today provided a business update for the second quarter ended June 30, 2018.
BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
In addition, the Company announced that based on the FDA’s responses, it plans to apply for dual indications, both opioid use disorder and alcohol use disorder, within the same application.
The submitted pre-IND package provides the FDA with current information on BICX102, as well as the proposed development plan.
BioCorRx Release: Company Retains Innovative Science Solutions To Guide FDA Regulatory Process For Its Naltrexone Products
BioCorRx To Present At The Singular Research 11th Annual Best Of The Uncovereds Investment Conference September 22nd
BioCorRx Announces Update From First Joint Steering Committee Meeting For Injectable Naltrexone Product
BioCorRx Announces Agreement With Dr. David Gastfriend To Provide Strategic Initiative And Corporate Development Consulting